Who is sponsoring NCT04957225?

NCT04957225 is sponsored by Karolinska Institutet.

What drugs are being tested in NCT04957225?

Interventions in NCT04957225: MIRAA (Multimodal Intensive Rehabilitation of Aphasia and Apraxia of speech).

What condition does NCT04957225 study?

NCT04957225 studies Aphasia, Apraxia of Speech, Stroke.

Is NCT04957225 still recruiting?

NCT04957225 is currently completed. Last updated 9 March 2023.

Last reviewed 2023-03-09 · How we verify

NCT04957225: MIRAA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MIRAA - Implementation of Intensive Rehabilitation of Aphasia and/or Apraxia of Speech in Swedish Healthcare

Completed NA Last updated 9 March 2023

What this trial tests

NA trial testing MIRAA (Multimodal Intensive Rehabilitation of Aphasia and Apraxia of speech) in Aphasia in 25 participants. Completed in 31 December 2022.

Timeline

10 March 2021

Primary endpoint
31 December 2022

31 December 2022

Quick facts

Lead sponsor	Karolinska Institutet
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	25
Start date	10 March 2021
Primary completion	31 December 2022
Estimated completion	31 December 2022
Sites	1 location across Sweden

Drugs / interventions tested

MIRAA (Multimodal Intensive Rehabilitation of Aphasia and Apraxia of speech)

Conditions studied

Aphasia — all drugs for Aphasia →
Apraxia of Speech — all drugs for Apraxia of Speech →
Stroke — all drugs for Stroke →

Sponsor

Karolinska Institutet

Who can join

18 and older, any sex, with Aphasia or Apraxia of Speech. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Positive outcomes have been shown following intensive treatment of speech and/or language impairment post stroke, but how to design intensive treatment programs to achieve optimal recovery and neuroplasticity changes needs to be further researched. The purpose of the MIRAA (Multimodal Intensive Rehabilitation of Aphasia and Apraxia of Speech) project is to study feasibility of intensive intervention for acquired aphasia and apraxia of speech (AOS) after stroke in the regular Swedish health-care according to the updated national guidelines from the Swedish National Board of Health and Welfare.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Reversing the Ruin: Rehabilitation, Recovery, and Restoration After Stroke.
Stockbridge MD, Bunker LD, Hillis AE. · · 2022 · cited 6× · PMID 36181577 · DOI 10.1007/s11910-022-01231-5

Verify or expand the search:

Other recruiting trials for Aphasia

Currently open trials in the same condition.

NCT07460037 — Chinese-Specific Speech Imagery Coding Using High-Density ECoG · NA · recruiting
NCT07397923 — Exploratory Evaluation of the Digital Therapeutic Device Zenicom for Subacute Stroke Aphasia · Phase 2 · recruiting
NCT07281313 — Aphasia Physical EXercise Study: Randomized Trial · NA · recruiting
NCT06990997 — Effects of Aphasia Identification Cards on Service Workers' Comprehension of People With Aphasia · NA · recruiting
NCT06974279 — Post-Stroke Aphasia TMS · NA · recruiting

Other Karolinska Institutet trials

Trials by the same sponsor.

NCT06359262 — Evaluating the Hope@School Prevention Program · NA · not yet recruiting
NCT07289490 — Bilateral vs Unilateral Inguinal Hernia Repairs With an Asymptomatic Inguinal Hernia in Bilateral Hernias · NA · not yet recruiting
NCT06894264 — Emotion Processing and Regulation in People With Intellectual Disability · NA · not yet recruiting
NCT07494266 — Safety of a Healthy Plant-based Diet With Higher Potassium Content, Compared to a Healthy Plant-based Diet With Limited · NA · not yet recruiting
NCT07442032 — Cardiovascular Phenotypes in Sepsis · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04957225 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Karolinska Institutet
Last refreshed: 9 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04957225.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing